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Background: We investigated the capacity of expanded cord blood-derived CD34+ hematopoietic progenitor cells
to undergo respiratory epithelial differentiation ex vivo, and to engraft and attenuate alveolar disruption in injured
newborn murine lungs in vivo.
Methods: Respiratory epithelial differentiation was studied in CD34+ cells expanded in the presence of growth
factors and cytokines (“basic” medium), in one group supplemented with dexamethasone (“DEX”). Expanded or
freshly isolated CD34+ cells were inoculated intranasally in newborn mice with apoptosis-induced lung injury.
Pulmonary engraftment, lung growth and alveolarization were studied at 8 weeks post-inoculation.
Results: SP-C mRNA expression was seen in 2/7 CD34+ cell isolates expanded in basic media and in 6/7 isolates
expanded in DEX, associated with cytoplasmic SP-C immunoreactivity and ultrastructural features suggestive of type
II cell-like differentiation. Administration of expanding CD34+ cells was associated with increased lung growth and,
in animals treated with DEX-exposed cells, enhanced alveolar septation. Freshly isolated CD34+ cells had no effect
of lung growth or remodeling. Lungs of animals treated with expanded CD34+ cells contained intraalveolar
aggregates of replicating alu-FISH-positive mononuclear cells, whereas epithelial engraftment was extremely rare.
Conclusion: Expanded cord blood CD34+ cells can induce lung growth and alveolarization in injured newborn
lungs. These growth-promoting effects may be linked to paracrine or immunomodulatory effects of persistent cord
blood-derived mononuclear cells, as expanded cells showed limited respiratory epithelial transdifferentiation.
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Premature infants treated with supplemental oxygen and
mechanical ventilation are at risk for bronchopulmonary
dysplasia (BPD), or chronic lung disease of the preterm
newborn, a complex and multifactorial condition character-
ized by an arrest of alveolar development [1-4]. Although
increased use of exogenous surfactant and antenatal
steroids, improved ventilatory strategies, and changes
in neonatal intensive care have modified its phenotype,* Correspondence: mdepaepe@wihri.org
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reproduction in any medium, provided the orBPD continues to be a significant health problem for
the increasing number of surviving extremely prema-
ture infants.
The role of stem cell therapy as an alternative or
complimentary approach for treatment or prevention of
chronic lung disease of the newborn remains largely
undetermined (reviewed in [5,6]). Cord blood might
represent an attractive source of stem cells for regenerative
therapy in newborns. Human umbilical cord blood stem
cells can be collected at no risk to the donor, have low
immune reactivity and low inherent pathogen transmission,
and are not subject to the social and political controversy
associated with embryonic stem cells. Cord blood stem cells
are particularly attractive in the newborn context where,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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be used as an autologous transplant in a contained system,
thus limiting the risk of infection or rejection. Cord blood
stem cell harvesting is expected to be most applicable to
newborns of more than 30-32 weeks’ gestational age; it may
be impossible to obtain sufficient amounts of cord blood at
younger ages due to the small size of cord and placental/
umbilical vessels.
Among the various types of stem cells that can be
procured from umbilical cord blood (CB), CD34+
hematopoietic progenitor cells are relatively uniformly
characterized, easily isolated, and have an excellent
and long-standing safety record after decades of use in
clinical bone marrow transplantation. We previously
demonstrated that freshly isolated human cord blood-
derived (CB) CD34+ hematopoietic progenitor cells are
capable of long term pulmonary engraftment, replication,
clonal expansion, and differentiation to alveolar type II cell-
like cells by apparent fusion-independent mechanisms fol-
lowing intranasal/intrapulmonary inoculation in newborn
mice [7]. Furthermore, we determined that the engrafted
cord blood-derived transdifferentiated alveolar type II cells
function as progenitor cells of the distal respiratory
unit, similar to endogenous type II cells [7]. This
proof-of-concept pilot study allowed us to establish
the in vivo transdifferentiation potential of CB-CD34+
cells. However, the small graft size used in that study
(1-2 x 105 cells/pup) did not allow definitive assessment
of the potential functional capacity of cord blood stem
cells to prevent or attenuate alveolar disruption in injured
newborn lungs.
Successful translation of alveolar epithelial cell therapy
to preclinical or clinical contexts may depend on our
capacity to deliver stem or progenitor cells in sufficient
quantity to achieve functional benefits. The main strategies
to augment graft size consist of either pooling of stem cells
from multiple donors or expansion of stem cells from a
single donor. While both methods have merit, and may well
be complimentary, ex vivo expansion seems a particularly
attractive technique in newborn infants as it might allow
transplantation of autologous cord blood-derived cells in a
fully contained system.
The aim of this study was to test the hypothesis that
CB-CD34+ cells, expanded ex vivo in conditions promoting
respiratory epithelial differentiation, retain their capacity
for pulmonary engraftment and respiratory epithelial
differentiation and can promote lung growth and
alveolarization in injured newborn lungs in vivo. For
ex vivo induction of respiratory epithelial differentiation,
CB-CD34+ cells were exposed to various factors known to
promote lung maturation, differentiation, growth, and/or
repair, including retinoic acid, keratinocyte growth factor,
GM-CSF and dexamethasone [8-17]. As in previous studies
[7,18], we chose the intranasal/intrapulmonary, rather thansystemic route of administration for delivery of stem cells.
The direct intrapulmonary delivery of stem cells may
represent a biologically more sound strategy for restoration
of the respiratory epithelium [18]. Furthermore, as many
preterm infants are intubated, intrapulmonary delivery via
the endotracheal tube is clinically relevant and within
the scope of the current practice of administration of
exogenous surfactant and antioxidants.
As model of neonatal lung injury, we used our previously
described conditional respiratory epithelium-specific
Fas-ligand (FasL) overexpressing transgenic mouse [19,20].
When FasL-mediated respiratory epithelial cell death is
targeted to the perinatal period, this novel and versatile
transgenic mouse model provides replication of both the
early apoptotic injury and subsequent alveolar simplifica-
tion typical of preterm infants with BPD [19,20].
Methods
Isolation and culture of CB-CD34+ cells
Umbilical cord blood (CB) CD34+ cells were isolated from
uncomplicated full-term cesarean deliveries at Women and
Infants Hospital according to protocols approved by the In-
stitutional Review Board, as described [7]. In accordance
with our previous experience, on average about 1.5 x 106
CB-CD34+ cells were harvested per placenta. CD34+
cell purity was greater than 95% and viability greater
than 92% following density gradient centrifugation and
immunomagnetic (MACS) sorting.
Freshly isolated CB-CD34+ cells were cultured in
liquid suspension according to a two-step expansion and
differentiation protocol. Initially, enriched CB-CD34+
cells were incubated in StemPro-34 Serum-Free Medium
(SFM) (Invitrogen, Carlsbad, CA) supplemented with the
following human recombinant factors: stem cell factor
(SCF, 100 ng/ml), IL-3 (50 ng/ml) and GM-CSF (25 ng/ml)
(all from Miltenyi Biotec) (“expansion” medium). Cells were
incubated in 25 cm3 vented tissue culture flasks in 5-10 mL
expansion media in a fully humidified atmosphere of 5%
CO2 at 37°C.
After 72 hours of culture in StemPro-34 SFM expansion
medium, cells were incubated in two types of culture media
aimed at inducing respiratory epithelial differentiation
(“differentiation” media). The following differentiation media
were assessed: StemPro-34 SFM medium, supplemented
with retinoic acid (RA, 0.01 μM) (Sigma, St. Louis, MO)
and keratinocyte growth factor (KGF, 0.01 μM, Sigma) in
addition to the human recombinant factors SCF, IL-3
and GM-CSF (“basic” medium) and StemPro basic
medium supplemented with dexamethasone (DEX) (Sigma)
at concentrations ranging between 10-5 and 10-7 M
(in 0.01% DMSO) (“DEX” medium). StemPro basic
medium with 0.01% DMSO (“DMSO” medium) served as
additional control for the dexamethasone cultures. At
three-day intervals, one-half volume fresh media was added
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from each flask were collected for analyses.
Analysis of expansion kinetics of cultured CB-CD34+ cells
Aliquots of cultured CB-CD34+ cells were taken at 3-day
intervals and stained with 0.4% Trypan Blue (vital dye)
(Life Technologies, Grand Island, NY). The total number of
live cells (unstained) was counted using a hemocytometer.
The growth rate was defined as the total cell number at a
particular time point divided by the cell number at the
preceding time point. The expansion index was deter-
mined by dividing the total cell number at a particular
time point by the total cell number on day 0 and reflects
the degree of amplification of the cell population. In three
experiments, the fraction of CD34+ cells at selected points
was analyzed by flow cytometry using FITC-labeled
anti-CD34 antibodies (Miltenyi Biotec, Cambridge, MA).
Analysis of respiratory epithelial differentiation of
cultured CB-CD34+ cells
The cellular morphology of cultured CB-CD34+ cells at
various time intervals after isolation was studied by phase
contrast optics and light microscopy of Giemsa-Wright
-stained cytospin preparations. Cytospin preparations from
selected time points were subjected to anti-surfactant
protein-C (SP-C) immunofluorescence analysis, using a
polyclonal anti-SP-C antibody (Abcam) according to
methods previously described [21]. In addition, CD34+
isolates from selected time points were studied by transmis-
sion electron microscopy. For ultrastructural studies, cell
pellets were fixed with 1.25% glutaraldehyde in 0.15 mol/L
sodium cacodylate buffer, postfixed with 1% osmium
tetroxide, and dehydrated through a graded ethanol series.
Ultrathin sections were stained with uranyl acetate/lead
citrate and viewed using a Philips 300 electron microscope
(Philips, Research, Eindhoven, the Netherlands).
Respiratory epithelial gene expression in expanded CD34
+ cells was estimated by semi-quantitative RT-PCR analysis
of expression of SP-C as marker gene of alveolar type II
cells. Total cellular RNA was extracted from CB-CD34+
cell lysates at various time points using Trizol reagent
(Invitrogen) and purified using the RNeasy MinElute
Cleanup kit (Qiagen, Valencia, CA). Total RNA (1 μg) was
reverse-transcribed using the SuperScript III First-Strand
Synthesis System (Invitrogen) according to the manufac-
turer’s protocol. Surfactant protein C (SP-C) and glyceral-
dehyde phosphate dehydrogenase (GAPDH, housekeeping
gene) were amplified by polymerase chain reaction (PCR).
The following primer sequences were used: SP-C: F: TGG
TCC TCA TCG TCG TGG TGA TTG; R: CCT GCA
GAG AGC ATT CCA TCT GGA AG (product size:
327 bp) and GAPDH: F: CCC TTC ATT GAC CTC AAC
TAC AT; R: ACG ATA CCA AAG TTG TCA TGG AT
(product size: 407 bp).Animal husbandry and tissue processing
The previously described lung-specific FasL overexpressing
transgenic mouse [19,20] was used as model for neonatal
lung injury/BPD. This model is based on a tetracycline-
dependent tet-on overexpression system to achieve
time-specific FasL transgene expression in the respira-
tory epithelium [19]. Transgenic (tetOp)7-FasL mice
(“responder line”) were crossed with CCSP-rtTA mice
(“activator line”) (kindly provided by Dr. J. Whitsett,
University of Cincinnati, OH) [22] to yield a mixed off-
spring of double transgenic (CCSP-rtTA+/(tetOp)7-FasL+)
and single transgenic (CCSP-rtTA+/(tetOp)7-FasL-) litter-
mates. Upon exposure to the tetracycline analogue, doxy-
cycline (Dox), double transgenic mice (CCSP+/FasL+)
exhibit marked pulmonary apoptosis, resulting in BPD-like
alveolar disruption [19]. The transgenic animals are
generated in a FVB/N genetic background and have an
intact immune system.
Dox (0.01 mg/ml) was added to the drinking water of
pregnant and/or nursing dams from embryonal day 14
(E14) to postnatal day 3 (P3; postnatal day P1 = day of
birth). Pups were genotyped at P2. Only double trans-
genic CCSP+/FasL + animals were used for these experi-
ments. The animals were sacrificed at post-inoculation
week 8 by pentobarbital overdose. Lungs were processed
as described [19]. All animal experiments were
conducted in accordance with institutional guidelines for
the care and use of laboratory animals.
Intranasal administration of CB-CD34+ cells to newborn mice
To determine the effects of ex vivo expansion on the
engraftment, differentiation and regenerative capacity of
CB-CD34+ cells, cultured cells were collected after
4-6 days of culture in differentiation media (i.e. 7 to 9 days
after isolation) for administration to Dox-treated CCSP+/
FasL + newborn mice with lung injury. At this time
point, the cell number was doubling, while still ap-
proximately 60% of cells had a CD34+ progenitor cell
immunophenotype. To prevent or minimize exposure
of the animals to DEX and other factors used during
the ex vivo expansion/differentiation, the cultured cells
were resuspended in PBS after collection. At postnatal
day 5 (P5), expanded CB-CD34+ cells from a single
donor (1 × 106 cells/pup) were delivered to Dox-treated
double transgenic CCSP+/FasL + pups by intranasal
administration, as previously described [18]. Experimental
animals received CD34+ cells from a single donor
expanded in basic medium or expanded in DEX medium
(basic medium supplemented with 10-6 M DEX). Animals
treated with expanded cells received 1 × 106 cells per pup.
Control animals received freshly isolated CD34+ cells
(0.5 × 106 cells/pup) or equal volume phosphate-buffered
saline (PBS) vehicle buffer. Intranasal inoculation was
performed at postnatal day 5 (P5) as this time point is
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injury and remodeling in Dox-treated double transgenic
CCSP+/FasL +mice.
Analysis of engraftment and cell fate of expanded CB-CD34+
cells in lungs of newborn mice
Engraftment of cord blood-derived cells was assessed at
8 weeks post- inoculation. The presence of CB-CD34+
cells or their progeny was studied by fluorescent in situ
hybridization (FISH) analysis using human-specific alu
probes and analyzed by confocal microscopy, as previously
described [7]. The proliferative activity of engrafted cord
blood-derived cells was assessed by combining human alu-
FISH analysis with anti-Ki67 immunohistochemistry [7].
In the absence of human-specific immunohistochemical
markers of alveolar type II cells, differentiation of CB-
CD34+ cells to alveolar type II cells was assessed by com-
bining anti-human cytokeratin staining (used as marker of
human, i.e. cord blood-derived epithelial cells) with
anti-prosurfactant protein-C (SP-C) (used as alveolar type
II cell marker) (ab28744, Abcam Inc., Cambridge, MA) , as
previously described [7]. In addition to standard epifluores-
cence microscopy, the sections were viewed by confocal
microscopy and slice or three-dimensional volume recon-
struction and projections were generated to ascertain the
veracity of co-localization phenomena, as described [18].
To study leukocyte differentiation of donor-derived cells,
sections were studied by immunoperoxidase method using
a human-specific anti-CD45 antibody (DAKO).
Analysis of effect of expanded CB-CD34+ cells on lung
growth and alveolarization
Morphometric assessment of growth of peripheral air-
exchanging lung parenchyma and contribution of the
various lung compartments (airspace versus parenchyma)
to the total lung volume was performed using stereological
volumetric techniques, as previously described [23,24]. The
inflated lung volume, V(lu), was determined according
to the Archimedes principle [25]. The areal density of
air-exchanging parenchyma, AA(ae/lu), was determined
by point-counting based on computer-assisted image
analysis. The total volume of air-exchanging parenchyma,
V(ae), was calculated by multiplying AA(ae/lu) by V(lu).
Alveolarization was quantified by computer-assisted
histomorphometric analysis of the mean cord length
(MCL), as described [19]. All morphometric assess-
ments were made on coded slides by a single observer
who was unaware of the experimental condition of the
animal analyzed.
Data analysis
Values are expressed as mean ± standard deviation (SD).
The significance of differences between groups was
determined with the unpaired Student’s t-test or ANOVAwith post-hoc Scheffe test where indicated. The significance
level was set at P < 0.05.
Results
Expansion kinetics of cultured CB-CD34+ cells
Enriched CD34+ cells were cultured in expansion media
for three days, followed by incubation in media aimed at
inducing respiratory epithelial differentiation (“basic”
and “DEX”). The cell growth rate, defined as cell number
at any given time point divided by the cell number at
the immediately preceding time point, was highest in the
first 2 weeks of culture for all groups and tended to be
higher for cells cultured in basic medium than for cells
cultured in DEX media (10-5 M in 0.1% DMSO)
(Figure 1). During the 21-day culture period, CD34+
cells in basic medium expanded on average more than
6,000-fold, whereas expansion rates were significantly
three-fold lower for cells incubated with DEX (Figure 1).
The expansion kinetics of DMSO-exposed cells were
comparable to those of cells incubated in basic medium
(Figure 1). As expected, expansion of CB-CD34+ cells
was associated with a progressive loss of the CD34+
immunophenotype. The fraction of CD34-positive cells
decreased from >95% on day 0 to 90 ± 2% on day 6, 36 ±
3% on day 9, and 8 ± 3% on day 12, as determined by flow
cytometry of 3 isolates expanded in DEX media.
Morphology of expanded CB-CD34+ cells
By phase contrast microscopy, expanded CB-CD34+
cells appeared round, with increasing variability in cell
size after one week in culture (Figure 2 C and D, inset).
Occasional pseudopodia-like cellular extensions were
noted in all preparations. Giemsa-Wright-stained cytospin
preparations allowed a more detailed morphological
analysis of expanding CB CD34+ cells. At day 0, freshly iso-
lated CB CD34+ cells appeared uniformly round, relatively
small and “lymphocyte-like” with a small amount of
cytoplasm and a high nuclear/cytoplasmic ratio (Figure 2A).
Short and slender membrane projections were noted. At
culture day 3, the cells appeared larger with more abundant
and basophilic cytoplasm (Figure 2B). Corresponding to the
observed early increase in cell growth rate at this time
point, brisk mitotic activity was noted (Figure 2B, arrow).
By culture day 15, the cells were significantly more
pleomorphic, suggestive of differentiation along divergent
hematopoietic pathways (Figure 2C-D). The cells displayed
distinct basophilic and eosinophilic tinctorial qualities,
associated with increased granularity and vacuolization of
the often voluminous cytoplasm (Figure 2C-D). The cellular
morphology of most cells was suggestive of myeloblast/
early promyelocyte differentiation, although lymphoid or
other lineage differentiation cannot be reliably distinguished
in these preparations based on morphology alone.


























































































































































Figure 1 Expansion kinetics of cultured CB-CD34+ cells. Time
course expansion of nucleated cells in basic medium, DEX medium,
or DMSO medium. Data are mean ± SD obtained from three
experiments performed in triplicate. *: P < 0.05; **: P < 0.02; º: P = 0.08
versus basic medium.
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medium (Figure 2C-D).
We then studied the ultrastructural features of freshly
isolated CB-CD34+ cells and expanded CB-CD34+ cells
after two weeks in culture. Freshly isolated CB-CD34+
cells appeared uniform in size and shape and resembled
large lymphocytes with a cell diameter ranging between
3.3 μm and 5.0 μm (average diameter: 4.29 ± 0.15 μm), a
high nuclear-cytoplasmic ratio, few cytoplasmic organelles,
and short, slender membrane projections (Figure 2E).
Occasionally, electron dense granules measuring about
50 nm in diameter were noted adjacent to the cells or
in submembranous vacuoles, consistent with residual,
partially endocytosed immunomagnetic beads utilized
for MACS sorting of the cells (Figure 2E, arrows).After two weeks in culture, the cells were found to be
significantly larger and more heterogeneous in size and
cellular composition (Figure 2F-H). Cells cultured in
DEX media were larger than those cultured in basic
media (average diameter: 9.35 ± 1.82 μm versus 7.30 ±
1.90 μm; P < 0.0001). The vast majority of cells displayed
evidence of hematopoietic differentiation along myeloid,
erythroid and other lineages, recognizable by their
specific cytoplasmic granules. In this background of
hematopoietic progenitor cells, scattered cells were seen
with features not readily classifiable according to any of
the hematopoietic lineages. These atypical cells showed
a large, often curved nucleus, prominent cytoplasmic
organelles, villous membrane projections, and/or vesicles
with occasional rudimentary electron-dense lamellar
structures reminiscent of prelamellar bodies of alveolar
type II cells (Figures 2F and 2H, arrows). Occasionally,
these rudimentary lamellated structures were present in
perimembranous location or attached to the outer cell
membrane, suggestive of exocytosis (Figure 2H, arrows).
These atypical cells did not contain the specific granules
characteristic of hematopoietic precursors. Conversely,
villous membrane projections and lamellated cytoplasmic
organelles, as seen in these atypical cells, were not seen in
identifiable myeloid or erythroid precursors.
Analysis of respiratory epithelial gene expression of
expanded CB-CD34+ cells
Immunofluorescence analysis of cytospin preparations
of expanded CB-CD34+ cells examined after 3 weeks in
culture revealed the presence of granular cytoplasmic SP-C
immunoreactive material in scattered cells (Figure 3A-B).
Although the proportion of cells exhibiting SP-C immuno-
reactivity was insufficient to allow formal quantitation
(<5% of total cells), their number appeared higher in DEX-
expanded preparations than in basic medium-expanded
preparations. Immunoreactivity was absent in preparations
exposed to isotype IgG control (Figure 3C).
Respiratory epithelial cell-like differentiation of expanded
CB-CD34+ cells was further assessed by semi-quantitative
RT-PCR analysis of SP-C gene expression. Three isolates
were incubated in DEX medium with DEX concentrations
ranging from 10-7M to 10-5M or basic medium. SP-C
expression was observed in the presence of DEX in all
three isolates, with highest levels of expression in asso-
ciation with DEX at 10-5M in 2/3 cases (Figure 3D)
and in association with DEX at 10-6M in the third case.
We then studied SP-C expression in seven randomly
selected isolates incubated in basic medium or DEX
medium (10-5 in DMSO). SP-C mRNA expression,
suggestive of alveolar epithelial type II cell differenti-
ation, was observed in 6/7 DEX-exposed CD34+ cell
isolates and in 2/7 basic medium-exposed isolates.
None of the isolates cultured for less than one week
Figure 2 Morphology of expanded CB-CD34+ cells. A-D. Cytospin preparations of cultured CB-CD34+ cells. A. Day 0. Cells appear lymphocyte-like
and uniform in size and shape. B. Day 3; basic medium. Amount of cytoplasm has increased. Mitotic activity is noted (arrow). C-D. Day 15; basic
(C) or DEX (D) medium (insets: corresponding phase contrast microscopy images). Cells are larger and more heterogeneous. Many cells display a
vacuolated cytoplasm with granular eosinophilic or basophilic cytoplasm. A-D: Giemsa-Wright stain; original magnification X 1,000. E-H. Ultrastructural
appearance of expanded CB-CD34+ cells. E. Day 0. Relatively small freshly isolated cells with sparse cytoplasm and scant organelles. Electron dense beads
are noted (incidental finding related to MACS cell sorting procedure) (arrows and inset). F-G. Day 15; basic (F) or DEX (G) medium. Cells are larger and
more variable in size and shape with more irregular nuclei and more complex cytoplasmic composition. Most cells display specific granules of different
size and electron density, suggestive of myeloid differentiation. The arrow in panel F depicts an atypical cell exhibiting a curved nucleus, microvilli, and
microvesicular cytoplasmic aggregates (inset). The arrow in panel G depicts an apoptotic cell. H. Day 15, DEX medium. Atypical cell showing irregular
curved nucleus, localized cytoplasmic aggregate of microvesicular structures, and microvilli, associated with evidence of exocytosis of lamellated material
(arrow and inset). E-H: (uranyl acetate/lead citrate stain; size bar = 2 μm).
Figure 3 Analysis of respiratory epithelial cell-like differentiation in expanded CB-CD34+ cells. A-C: Immunofluorescence analysis of surfactant
protein-C expression in expanded CB-CD34+ cells, day 21, showing SP-C immunoreactivity (red) in cells cultured in DEX medium (A) and basic
medium (B). C: Isotype IgG control. DAPI counterstain (blue). Scale bar = 20 μm. D. RT-PCR analysis of surfactant protein-C gene expression in
expanded CB-CD34+ cells exposed to Dex at concentrations ranging from 10-7M to 10-5M. Shown are the results of two representative isolates.
Highest SP-C expression of SP-C (327 bp) is seen in the presence of Dex at 10-5M. Positive (human lung) and negative controls (omission reverse
transcriptase, H2O control) were included. The housekeeping gene GAPDH (407 bp) was included as loading control. E: RT-PCR analysis of surfactant
protein-C gene expression in expanded CB-CD34+ cells. Shown are the results of one representative isolate. Expression of SP-C is seen in the presence
of dexamethasone (DEX, 10-5M) after 15, 18 and 21 days of culture. Controls were as described under D.
Mao et al. Respiratory Research 2013, 14:37 Page 6 of 13
http://respiratory-research.com/content/14/1/37
Mao et al. Respiratory Research 2013, 14:37 Page 7 of 13
http://respiratory-research.com/content/14/1/37showed detectable SP-C expression. Results of a representa-
tive isolate are shown in Figure 3E.
Analysis of engraftment of expanded CB-CD34+ cells in
lungs of newborn mice
The collective results from the previous morphologic and
gene expression studies suggest that culture of CB-CD34+
cells in optimal conditions, achieved by exposure to KGF,
retinoic acid and dexamethasone, can induce alveolar
epithelial type II cell-like differentiation ex vivo. In the sec-
ond part of this study, we investigated whether expanding
CB-CD34+ cells maintain the previously demonstrated
potential of freshly isolated CB-CD34+ cells to engraft and
transdifferentiate to respiratory epithelial cells in vivo.
Engraftment was studied 8 weeks after intranasal
inoculation of cultured CB-CD34+ cells by FISH analysis
for human alu sequences [7]. Alu-FISH-positive cells
were readily identified in all recipient animals, although
the recovery rates, cellular location, and morphologic ap-
pearances varied widely between the different study groups.
In recipients of expanded CB-CD34+ cells (basic or DEX)
virtually all alu-FISH-positive nuclei were free-floating in
the airspaces, often in aggregates of cells with homoge-
neous, small-sized nuclei (Figure 4B-C). In animals treated
with freshly isolated CB-CD34+ cells, in contrast, the vast
majority of FISH-positive nuclei was relatively large-sized
(equivalent in size to neighboring alveolar epithelialFigure 4 Analysis of engraftment and proliferation of CB-CD34-derive
(positive control) showing nuclear positivity in all cells. B: Representative m
basic medium showing a cluster of alu-FISH-positive cells within airspace. C
of alu-FISH-positive cells along the alveolar wall, admixed with larger-sized,
(green) with DAPI counterstain (blue). D-F: Alu-FISH analysis combined with
animal treated with freshly isolated CD34+ cells, showing relatively large-si
E. Lungs of animal treated with CD34+ cells expanded in basic medium sh
Proliferative activity is present in these CD34-derived cells (arrow). F. Lungs
Ki67-positivity in FISH-positive intraalveolar cells (arrow). Several proliferatin
combined with anti-Ki67 immunofluorescence (red); DAPI counterstain (blucell nuclei) and localized to the alveolar wall (Figure 4D).
Although the number of epithelial-appearing alu-FISH
-positive nuclei observed was small in all groups, the
amount of engrafted epithelial-like cells appeared much
lower following administration of expanded cells than
after administration of freshly isolated CB-CD34+ cells.
Analysis of proliferation
Proliferation of engrafted cord blood-derived cells was
assessed by combining human-specific alu-FISH analysis
with anti-Ki67 immunofluorescence staining. In concord-
ance with our previous observations [7], proliferative
activity could be observed in a small fraction (<5%) of
cord blood-derived type II-cell-like engrafted cells in
animals treated with freshly isolated CD34+ cells
(Figure 4D). In animals treated with expanded cells,
proliferative activity in cord-blood-derived cells was
overall more prevalent, and readily visualized in single
or clustered lymphoid/myeloid-like mononuclear cells
within the airspaces (Figure 4E-F).
Analysis of cell fate of expanded CB-CD34+ cells in lungs
of newborn mice
Analysis of respiratory epithelial differentiation
To determine the capacity of CB-CD34+ cells to
undergo respiratory epithelial differentiation, we performed
double immunofluorescence labeling studies combiningd cells. A-C: Alu-FISH analysis. A: Human postmortem lung tissue
icrograph of lungs of animal treated with CD34+ cells expanded in
. Lung of animal treated with DEX-expanded cells showing collection
FISH-negative murine alveolar macrophages. A-C: alu-FISH analysis
anti-Ki67 immunofluorescence. D. Representative micrograph of
zed proliferating alu-FISH positive cells within the alveolar wall (arrows).
owing a large cluster of alu-FISH-positive cells free within the airspace.
of animal treated with DEX-expanded CD34+ cells, similarly showing
g FISH-negative murine cells are noted. D-F: alu-FISH analysis (green)
e).
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derived epithelial cells) with SP-C staining (as marker of
respiratory epithelial cells). In all study groups, rare cells
exhibiting colocalization of human cytokeratin and SP-C
could be identified, suggestive of transdifferentiation of
cord blood-derived cells to surfactant-producing alveolar
epithelial cells (Figure 5). Cytokeratin immunoreactivity
was absent in surrounding murine alveolar epithelial type II
cells, confirming the human-specificity of the anti-keratin
antibody. Three-dimensional volume reconstruction and
volume slicing with x/y/z axis analysis confirmed unequivo-
cal localization of the SP-C-positive material within the
cells (Figure 5). These cord blood-derived type II-like cells
were sparse in all groups, but were in particular exceedingly
rare in animals treated with expanded (DEX or basic) cells
(0.32 ± 0.35 and 0.25 ± 0.38 cells per 10 40x high-power
fields, respectively; based on four animals per group)
compared with those treated with freshly isolated cells
(0.62 ± 0.53 per 10 40x high-power fields, difference
not statistically significant).
Analysis of leukocyte differentiation
The alu-FISH-positive cells detected as single or clustered
cells within the airspaces of animals treated with expanded
cells were morphologically suggestive of mononuclearFigure 5 Analysis of alveolar epithelial cell-like transdifferentiation of
subjected to combined anti-human-cytokeratin (green) and anti-mouse/hu
micrograph of lungs of animal treated with freshly isolated CD34+ cells. SP
(arrows). C: Similar double immunofluorescence staining showing one exce
observed in an animal treated with expanded cells. A-C. Merging of the im
CK-positive, human-derived epithelial cells. The SP-C-positive material is coa
Colocalization persists at all three-dimensional volume angles analyzed. Vol
colocalization of green and red signals in the same cell, resulting in a yello
of SP-C-positive material in this human CK-positive, human cord blood-der
with anti-human/mouse SP-C stain (red), DAPI counterstain. Scale bar = 10leukocytes. Lung sections were studied by immunohis-
tochemical analysis using an antibody specific for the
human CD45 antigen (LCA, leukocyte common antigen).
Scattered cord blood-derived CD45-positive mononuclear
cells, consistent with lymphoid cells or monocytes/
macrophages were identified within the airspaces or
along the alveolar wall (Figure 6A). Absence of CD45
immunoreactivity in murine thymic lymphocytes
(Figure 6B) and strong immunoreactivity in human
tonsillar lymphocytes (Figure 6C) confirmed the specificity
of the antibody for CD45 antigen of human origin. The
combined immunohistochemical results indicate that a
significant fraction of CD34-derived cells persist as
intraalveolar non-epithelial cells, including leukocytes.
Analysis of effect of expanded CB-CD34+ cells on lung
growth and alveolarization
The lung volume, V(lu), was larger in animals treated with
CD34+ cells expanded in basic media than in sham con-
trols (P < 0.05). A similar trend was seen in animals treated
with DEX-expanded cells (Table 1). Computer-assisted
stereological volumetry was applied to determine the
relative contributions of the various lung compartments
(peripheral air-exchanging parenchyma versus airspace) to
the total lung volume. The areal density of air-exchangingCB-CD34-derived cells. Confocal fluorescence microscopy of lungs
man SP-C (red) immunofluorescence staining. A-B: Representative
-C-positive human-derived epithelial cells were readily visualized
edingly rare SP-C-immunoreactive human-derived cell (arrow)
ages shows colocalization of granular SP-C-positive material in the
rsely granular, consistent with surfactant-containing lamellar bodies.
ume slices along the xz (horizontal) and yz (vertical) axes both show
w-orange composite signal and confirming the unequivocal presence
ived epithelial cell. A-C: Anti-human cytokeratin stain (green) combined
μm.
Figure 6 Analysis of leukocyte differentiation of CB-CD34+ cells. Immunohistochemical analysis of leukocyte differentiation using a
human-specific anti-CD45 (leukocyte common antigen) antibody. A. Representative micrograph of lungs of animal treated with DEX-expanded
CB-CD34+ cells at post-inoculation week 8. Scattered CD45-positive mononuclear cells are noted along the alveolar wall. CD45-immunoreactivity is
absent in murine thymic lymphocytes (negative control) (B) and diffusely positive in human lymphocytes (C, human tonsil, positive control), confirming
the human-specific nature of the antibody. A-C: avidin-biotin peroxidase staining, hematoxylin counterstain. Original magnification: X400.
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http://respiratory-research.com/content/14/1/37parenchyma, AA(ae/lu), which represents the parenchymal
tissue fraction, tended to be larger in animals treated with
DEX-expanded CD34+ cells than in the other groups.
The total volume of air-exchanging parenchyma, V(ae),
which takes into account both V(lu) and AA(ae/lu), was
significantly 25% larger in animals with CD34+ cells
expanded in basic media (P < 0.02) and 30% larger in
animals with DEX-expanded CD34+ cells (P < 0.05) than in
sham controls. Similarly, V(ae) normalized to body weight
[V(ae)/BW] was significantly larger in animals treated with
both types of expanded CD34+ cells compared with sham
controls (P < 0.01). In contrast, treatment with fresh CD34+
cells had no effect on V(ae) or V(ae)/BW (Table 1).
The lung histology of Dox-treated double transgenic
CCSP+/FasL + animals treated with CB-CD34+ cells
expanded in basic media appeared similar to that of
animals treated with freshly isolated CB-CD34+ cells,
and sham (PBS) controls (Figure 7 A-C). In these three
groups, the airspaces were markedly dilated and simplified,
resulting in an emphysematous appearance (Figure 7 A-C).
Lungs of double transgenic animals treated with DEX-
expanded cells showed smaller airspaces and a more
complex alveolar network (Figure 7 D). Small numbersTable 1 Biometry and volumetry data
PBS (8) CD34+ Fresh
Body wt (g) 26.37 ± 2.76 21.00 ± 2.95
V(lu) (μl) 669 ± 161 595 ± 105
AA(ae/lu) 21.3 ± 4.7 20.2 ± 3.0
V(ae) (μl) 136 ± 23 118 ± 12
V(ae)/BW (μl/g) 5.33 ± 0.48 5.69 ± 0.82
Animals were treated with freshly isolated CB-CD34+ cells (0.5 x 106 cells/pup) or C
Sham controls received equal volume PBS.
Values represent mean ± SD of (n) animals per group.
V(lu): lung volume; AA(ae/lu): areal fraction of air-exchanging parenchyma; V(ae): vo
*: P < 0.05; **: P < 0.01 versus PBS-treated sham controls.
(Student-t test).of scattered alveolar macrophages, were seen in all groups
and were usually limited to the subpleural regions
(not shown). There was no other histologic evidence
of interstitial or intraalveolar inflammation in any of
these groups.
The degree of alveolarization was estimated morpho-
metrically by determination of the mean cord length
(MCL) (Figure 7, top). The MCL was significantly 48%
smaller in animals treated with DEX-expanded CD34+ cells
than in sham controls (36.1 ± 7.0 μm versus 53.5 ± 9.5 μm,
P < 0.001), indicative of significantly enhanced alveolar sept-
ation in animals treated with DEX-exposed CD34+ cells.
The MCL of animals treated with CD34+ cells expanded in
basic medium was similar to that of animals treated with
fresh CD34+ cells or sham animals (Figure 7, top).
Discussion
We recently reported that freshly isolated and intranasally
delivered cord blood-derived CD-34+ cells (CB-CD34+) are
capable of stable engraftment, clonogenic expansion, and
respiratory epithelial transdifferentiation in injured new-
born lungs [7]. In the present study, we investigated the
therapeutic potential of ex vivo expanded CB-CD34+ cells(3) CD34+ Basic (12) CD34+ Dex (8)
* 25.50 ± 4.43 23.01 ± 3.29*
814 ± 153* 738 ± 113
21.1 ± 3.1 24.0 ± 4.9
170 ± 31* 177 ± 43*
6.84 ± 1.35** 7.45 ± 1.92**
B-CD34+ cells expanded in basic medium or DEX medium (1-2 x 106 cells/pup).
lume of air-exchanging parenchyma.
Figure 7 Analysis of alveolarization. Top. Morphometric analysis
of mean cord length (MCL). Values represent mean ± SD of at least 3
animals per group. *: P < 0.01 versus PBS-treated sham controls
(ANOVA with post hoc Scheffe test). Bottom. Representative
micrographs showing lung parenchyma of animals treated with PBS
(sham, A), fresh CB-CD34+ cells (B), CB-CD34+ cells expanded in
basic medium (C) or CB-CD34+ cells expanded in DEX medium (D),
8 weeks post inoculation. Animals treated with DEX-expanded CD34
+ cells (D) showed more advanced alveolar architectural remodeling
with more complex alveolar septation than animals of the other
study groups (A-C). Hematoxylin-eosin staining, original
magnification: X200.
Mao et al. Respiratory Research 2013, 14:37 Page 10 of 13
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whether expanding CB-CD34+ cells can be induced to go
undergo respiratory epithelial differentiation in culture.
When exposed to conditions conducive to respiratory
epithelial differentiation, including the appropriate
cocktail of cytokines, growth factors, and glucocorticoids
(dexamethasone, DEX), CB-CD34+ cells demonstrated an
innate potential to undergo respiratory epithelial cell-like
differentiation, as evidenced by SP-C mRNA expression in
virtually all DEX-exposed cell isolates examined. Respira-
tory epithelial cell-like transdifferentiation of a subset of
DEX-expanded cells was confirmed by focal cytoplasmic
presence of immunoreactive SP-C protein, as well as ultra-
structural features reminiscent of alveolar type II cell-like
differentiation, such as prelamellar body-like organelles,
microvilli, and apparent exocytosis of lamellated elec-
tron dense material. The effect of Dex exposure on SP-Cexpression was studied for concentrations ranging between
10-5 and 10-7M (100-10.000 nM). In this limited dose
response study, SP-C expression was highest in cells
exposed to 10-5M/10-6M Dex. As a reference, the Dex
concentration used for ex vivo stem cell and/or erythroid
progenitor cell expansion in various reported experimental
or clinical models ranges around 10-6M [26-28]. The
customary Dex concentration used to study human
alveolar type II cell differentiation in vitro is considerably
lower (10nM, 10-8M) [17].
Sueblinvong et al. [29] previously reported respiratory
epithelial gene expression, including SP-C expression, in
human cord blood-derived mesenchymal stem cells cul-
tured in specialized airway growth media and/or specific
growth factors such as KGF and retinoic acid. Similarly,
Berger et al. [30,31] reported respiratory epithelial differ-
entiation in cord blood-derived multilineage progenitor
cells cultured and differentiated in standard mesenchy-
mal stem cell growth medium and small airway growth
medium (SAGM), respectively. To our knowledge, this is
the first study to demonstrate that cord blood-derived
CD34+ cells, as well, have the capacity to undergo
in vitro respiratory epithelial cell-like differentiation
when exposed to the appropriate differentiation agents.
Of note, the current in vitro studies demonstrate that cord
blood-derived CD34+ cells are capable of development of
a type II cell-like phenotype in the absence of respiratory
epithelial cells or their cell components (such as vesicles)
and thus confirm our prior in vivo observation [7] that
transdifferentiation of CB-CD34+ cells to type II cell-like
cells can occur by fusion-independent mechanisms.
The second aim of this study was to determine
whether CB-CD34+ cells, briefly expanded ex vivo, have
the capacity to engraft and improve alveolar remodeling
in injured newborn murine lungs in vivo. Consistent
with our belief that direct intrapulmonary delivery of
stem cells represents a biologically sound and clinically
relevant strategy for restoration of injured respiratory
epithelium, we chose the intranasal/intrapulmonary, rather
than systemic route of administration for delivery of stem
cells in this study, as described in prior studies [7,18]. The
cell fate and effects of CB-CD34+ cells expanded ex vivo in
basic or DEX media were compared with those of freshly
isolated CB-CD34+ cells.
In agreement with our previous study [7], intranasal
delivery of freshly isolated CD34+ cells led to mod-
est but stable engraftment of SP-C immunoreactive,
transdifferentiated alveolar type II cell-like cells.
Engraftment in the form of transdifferentiated alveolar
epithelial-like cells was negligible following delivery of
expanded CD34-derived cells, whether cultured in
DEX or basic media. Instead, the vast majority of
expanded cells or their progeny were recovered as
aggregates of non-epithelial, at least partly leukocytic
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within the airspaces. It needs to be stressed that studies
based on detection of human-specific markers in homoge-
nized lung tissues may have concluded that inoculation of
expanded CD34+ results in massive “engraftment” of cord
blood-derived cells. However, the term engraftment in the
strictest sense may be better reserved for unequivocal stable
integration of donor-derived cells within the alveolar wall,
preferably with demonstrated evidence of respiratory
epithelial transdifferentiation and clonogenic expansion.
Administration of expanded cells, whether grown in
basic or DEX media, was associated with significant lung
growth at 8 weeks post-transplantation, as determined by
stereological volumetry of the air-exchanging parenchyma.
The lung growth was associated with enhanced alveolar
septation in animals treated with DEX-expanded cells,
but not in those treated with cells expanded in basic
medium in the absence of DEX. Administration of
freshly isolated CB-CD34+ cells, while resulting in more
effective engraftment and transdifferentiation, did not
affect either lung growth or alveolar development.
While the capacity of DEX-expanded cells to promote
lung growth and alveolar remodeling in injured newborn
lungs is highly encouraging, the mechanisms underlying
these beneficial effects remain unclear.
In view of the negligible engraftment and trans-
differentiation rates achieved with expanded cells, it
is unlikely that the positive impact is related to regeneration
of injured alveolar epithelium by transdifferentiated type II
cell-like cells. Rather, it is plausible that the growth-
promoting effects of DEX-expanded cells are linked to
paracrine effects related to factors produced by the ob-
served relatively abundant cord blood-derived intraalveolar
mononuclear cells. By analogy, the beneficial effects of a
variety of stem or progenitor cells types in a wide range
of lung injury models have mostly been attributed to
cell-derived paracrine factors, as lung engraftment of
stem or progenitor cells has been reported as much less
than 5% in the majority of studies (reviewed in [5]).
Paracrine mechanisms of action have been studied most
extensively in mesenchymal stem cells. The beneficial
effects of stem cell-derived paracrine factors, such as
interleukin (IL)-10, IL1ra, KGF, prostaglandin E2,
tumor necrosis factor-α stimulated gene/protein 6, and
others, have been linked to their anti-inflammatory,
immunomodulatory and/or growth promoting functions
(reviewed in [32]).
It needs to be emphasized that inherent limitations of
our experimental model, which is based on intranasal
stem cell delivery to an immunocompetent host, may
lead to underestimation of the full therapeutic potential
of cord blood-derived stem cell therapy in the clinical
context. The intranasal cell administration method is
inevitably inefficient: a significant and highly variableproportion of intranasally inoculated cells are lost by
spillage through mouth or gastrointestinal tract. If
translation of this preclinical study to the newborn context
becomes a reality, preterm newborns are expected to
receive autologous stem cells via an endotracheal tube,
which will eliminate the two major sources of graft loss
in our experimental model.
While the FasL transgenic mouse model is a valid
model of neonatal lung injury [19], it is centered on a
human-to-mouse xenograft in an immunocompetent
mouse strain. As we previously demonstrated, a large
fraction of the graft is eliminated by host rejection
during the early post-transplant period, [7,18]. However,
in concordance with other groups who demonstrated
similar long-term persistence of human-derived stem cells
in immunocompetent rodent (rat or mouse) lungs or other
organs [33-35], we were able to detect human-derived cells
up to 8 weeks after inoculation. The mechanisms whereby
(a subset of ) human-derived cells can persist in an im-
munocompetent rodent host, even in small amounts,
remain to be determined. We speculate that at least some
of the reported functional or phenotypic mechanisms by
which tumor stem cells (TSCs) evade immunosurveillance
and immune-mediated rejection may be implicated. Such
reported mechanisms include altered immunogenicity of
TSCs, production of TSC-derived regulatory molecules,
and interaction of TSCs with tumor-infiltrating immune
cells (reviewed in [36]).
Other limitations of this study are acknowledged. First,
our study was restricted to the use of a single, arbitrarily
selected stem cell loading dose per study group. Future
dose-response studies will be required to determine the
optimal dose of stem cells to achieve functional amelior-
ation of alveolar remodeling for each stem cell type and
delivery route studied. Second, the long-term outcome of
intranasal stem cell delivery remains unclear. The effects of
the long-term chimerism created by the intrapulmonary
persistence of actively replicating hematopoietic elements
with presumed ongoing paracrine effects certainly deserve
future experimental attention. Third, analysis of respiratory
epithelial differentiation, both ex vivo and in vivo, was
mainly focused on surfactant protein-C expression as
marker of alveolar type II cell differentiation. Whether the
respiratory epithelial-like cells derived from CB-CD34+
cells have additional morphologic, biochemical or func-
tional characteristics of alveolar epithelial cells remains
unclear. Fourth, the effects of stem cell delivery on alveolar
remodeling were limited to morphometric assessment of
alveolar septation. While mean cord length (MCL) is an
accepted measure of alveolar remodeling in newborn lungs,
and increased alveolar septation is a highly encouraging
predictor of ameliorated functional outcome, future studies
will be needed to establish the functional effects of stem cell
therapy. Fifth, this study only investigated the fate and
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preterm cells, highly relevant in translational context of
preterm lung injury, remain undetermined. Finally, this
study was limited to the use of CD34+ hematopoietic
progenitor cells. The use of other cord blood-derived
stem cells, in particular mesenchymal stem cells or their
secreted components, alone or in combination with
CD34+ cells, needs to be explored.Conclusions
Our results suggest that cord blood-derived CD34+ cells,
when cultured in the presence of growth factors, cytokines,
retinoic acid and glucocorticoids, have the (limited)
potential to undergo fusion-independent differentiation to
alveolar epithelial cell-like cells in vitro. Ex vivo expanded
CD34+ cells appear to lose their engraftment potential
following intrapulmonary delivery in vivo; instead, they tend
to persist long-term as an actively replicating population of
intraalveolar mononuclear cells. By currently undetermined
mechanisms, intrapulmonary delivery of DEX-expanded
cells promotes growth and alveolar remodeling of injured
newborn lungs. The suggestion that expanded cord
blood-derived CD34+ cells are capable of rescuing
alveolar development in injured newborn lungs, at least in
part, opens exciting avenues for future preclinical studies.
Such studies will need to focus on the refining of ex vivo
expansion techniques to determine the delicate balance
between cell growth, retention of critical stemness charac-
teristics of CD34+ cells (i.e. potential for self renewal and
engraftment), and appropriate lineage selection.
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